New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Daffodils by Artemis is a premiere luxury birthing centre offering mother and child care services.
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
The capital expansion program commenced in June 2022 and is expected to complete in 2024
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.
Subscribe To Our Newsletter & Stay Updated
